Lakefront Biotherapeutics (LKFT) Change in Account Payables (2015 - 2022)

Lakefront Biotherapeutics (LKFT) has reported Change in Account Payables for 5 consecutive years, with -$67.5 million the latest figure, recorded in Q2 2020.

• In Q2 2020, Change in Account Payables fell 277.23% year-over-year to -$67.5 million; the TTM figure through Jun 2020 stood at -$109.1 million (down 564.9% YoY), while the FY2025 annual figure was $39.4 million, up 168.94% from the prior year.
• Change in Account Payables declined to -$67.5 million in Q2 2020 per LKFT's latest filing, from $27.6 million in the prior quarter.
• Across five years, Change in Account Payables topped out at $5.8 billion in Q2 2017 and bottomed at -$6.2 billion in Q3 2017.
• Historically, Change in Account Payables has averaged -$33.1 million across 5 years, with a median of -$88910.7 in 2016.
• Annual changes were most pronounced in 2017 — Change in Account Payables surged 55900.85% — and 2018, when it slumped 540.19%.
• Lakefront Biotherapeutics' Change in Account Payables stood at -$10.4 million in 2016, then soared by 225.15% to $13.1 million in 2017, then plunged by 540.19% to -$57.5 million in 2018, then slumped by 187.28% to -$165.2 million in 2019, then jumped by 59.15% to -$67.5 million in 2020.
• Business Quant data shows LKFT's Change in Account Payables at -$67.5 million in Q2 2020, $27.6 million in Q1 2020, and -$165.2 million in Q4 2019.